Quarterly ResultAug 5, 2026, 07:48 AM
Bioventus Q2 Net Income +348% to $33.4M; Diluted EPS $0.47
AI Summary
Bioventus Inc. reported strong financial results for the second quarter and first half of 2026. For Q2 2026, net sales increased to $153.2 million, and net income attributable to Bioventus Inc. significantly grew to $33.4 million, resulting in diluted EPS of $0.47. The company also reduced its long-term debt by making substantial discretionary prepayments on its 2025 Term Loan.
Key Highlights
- Q2 2026 Net Sales increased 3.76% to $153.2 million from $147.7 million YoY.
- Q2 2026 Net Income attributable to Bioventus Inc. surged 348.33% to $33.4 million from $7.5 million YoY.
- Q2 2026 Diluted EPS rose 327.27% to $0.47 from $0.11 YoY.
- H1 2026 Net Sales increased 5.07% to $285.3 million from $271.5 million YoY.
- H1 2026 Net Income attributable to Bioventus Inc. grew 658.07% to $36.6 million from $4.8 million YoY.
- H1 2026 Diluted EPS increased 642.86% to $0.52 from $0.07 YoY.
- Long-term debt (less current portion) decreased by 17.65% to $229.7 million from $279.0 million since Dec 31, 2025.
- Made discretionary prepayments of $42.0 million on the 2025 Term Loan during H1 2026.
Price Impact
More from BVS